Pacira BioSciences Income Statement (2010-2026) | PCRX

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	135.59M	127.72M	159.19M	157.99M	169.41M	167.47M	-479.61M	160.34M	169.47M	163.93M	181.24M	167.12M	178.02M	168.57M	187.25M	168.92M	181.10M	179.52M	196.87M	177.38M
Cost of Revenue (Quarter)	35.25M	34.65M	39.01M	36.07M	50.63M	50.68M	61.92M	49.02M	48.21M	39.75M	47.69M	47.42M	44.26M	38.86M	39.89M	34.31M	40.87M	34.28M	40.30M	36.41M
Gross Profit (Quarter)	100.34M	93.07M	120.19M	121.92M	118.78M	116.79M	-541.53M	111.32M	121.26M	124.18M	133.55M	119.70M	133.76M	129.71M	147.37M	134.62M	140.23M	145.24M	156.57M	140.96M
Operating items
Amortization - Intangibles (Quarter)	2.00M	2.00M	7.65M	14.32M	14.30M	14.32M	14.29M	14.32M	14.30M	14.30M	14.32M	14.30M	14.32M	14.30M	14.32M	14.30M	14.32M	14.32M	14.30M	14.32M
Research & Development (Quarter)	12.57M	11.58M	15.51M	21.61M	26.28M	19.41M	17.50M	17.14M	18.82M	20.83M	19.46M	18.24M	20.34M	19.10M	23.90M	25.34M	28.20M	25.97M	37.45M	28.07M
Selling, General & Administrative (Quarter)	50.81M	47.86M	52.15M	64.26M	65.00M	61.28M	63.97M	70.84M	64.85M	67.95M	65.80M	72.03M	68.13M	74.33M	79.61M	86.78M	88.58M	91.80M	101.61M	93.94M
Restructuring Costs (Quarter)							10.90M		0.94M	0.20M	-1.45M	1.90M	2.73M	-1.77M	4.83M	6.19M	0.63M	6.79M	0.85M
Other Operating Expenses (Quarter)	37.36M	36.85M	87.31M	54.73M	46.89M	65.49M	89.47M	75.45M	44.98M	57.23M	64.26M	61.74M	58.58M	216.43M	54.21M	-6.19M	55.19M	48.60M	54.62M	2.28M
Operating Expenses (Quarter)	100.75M	96.29M	154.98M	140.60M	138.18M	146.18M	181.85M	163.43M	129.59M	146.21M	148.08M	153.91M	149.78M	308.10M	162.55M	166.93M	172.60M	173.15M	194.53M	170.47M
Operating Income (Quarter)	34.84M	31.43M	4.21M	17.39M	31.23M	21.29M	-9.89M	-3.09M	39.88M	17.72M	33.17M	13.21M	28.24M	-139.53M	24.70M	1.99M	8.50M	6.36M	2.34M	6.90M
EBIT (Quarter)	34.84M	31.43M	4.21M	17.39M	31.23M	21.29M	-9.89M	-3.09M	39.88M	17.72M	33.17M	13.21M	28.24M	-139.53M	24.70M	1.99M	8.50M	6.36M	2.34M	6.90M
Non-operating items
Interest & Investment Income (Quarter)	0.22M	0.18M	0.08M	0.27M	0.25M	1.23M	2.79M	3.14M	2.11M	2.77M	3.42M	3.90M	4.75M	5.48M	5.55M	6.89M	5.01M	8.53M	2.29M	1.93M
Other Non Operating Income (Quarter)	-2.40M	-0.05M	-0.07M		-0.65M		11.37M	-16.90M	-0.27M		-16.23M	-0.16M	7.52M		-7.89M	4.40M		-0.11M	-0.17M	-0.14M
Non Operating Income (Quarter)	-2.40M	-7.20M	-0.07M	-10.10M	-9.23M	-19.22M	0.08M	-0.01M	-0.27M	-0.42M	-25.27M	0.43M	-0.04M	-0.12M	-9.82M	6.72M	-10.74M	3.16M	-6.07M	-1.90M
Net income details
EBT (Quarter)	25.65M	24.23M	-6.20M	7.29M	22.01M	2.07M	-18.07M	-26.47M	37.85M	16.60M	33.72M	13.64M	36.58M	-138.86M	25.53M	8.71M	-1.93M	9.52M	0.57M	5.00M
Tax Provisions (Quarter)	6.57M	6.57M	-1.07M	0.47M	2.13M	2.76M	-7.97M	-6.94M	12.09M	5.74M	8.85M	4.66M	17.70M	4.61M	9.48M	3.89M	2.92M	4.09M	-1.07M	2.08M
Profit After Tax (Quarter)	19.08M	17.66M	-5.13M	6.83M	19.88M	-0.69M	-10.10M	-19.54M	25.76M	10.86M	24.87M	8.98M	18.89M	-143.47M	16.04M	4.81M	-4.85M	5.43M	1.64M	2.92M
Income from Continuing Operations (Quarter)	19.08M	17.66M	-5.13M	6.83M	19.88M	-0.69M	-10.10M	-19.54M	25.76M	10.86M	24.87M	8.98M	18.89M	-143.47M	16.04M	4.81M	-4.85M	5.43M	1.64M	2.92M
Consolidated Net Income (Quarter)	19.08M	17.66M	-5.13M	6.83M	19.88M	-0.69M	-10.10M	-19.54M	25.76M	10.86M	24.87M	8.98M	18.89M	-143.47M	16.04M	4.81M	-4.85M	5.43M	1.64M	2.92M
Income towards Parent Company (Quarter)	19.08M	17.66M	-5.13M	6.83M	19.88M	-0.69M	-10.10M	-19.54M	25.76M	10.86M	24.87M	8.98M	18.89M	-143.47M	16.04M	4.81M	-4.85M	5.43M	1.64M	2.92M
Net Income towards Common Stockholders (Quarter)	19.08M	17.66M	-5.13M	6.83M	19.88M	-0.69M	-10.10M	-19.54M	25.76M	10.86M	24.87M	8.98M	18.89M	-143.47M	16.04M	4.81M	-4.85M	5.43M	1.64M	2.92M
Additional items
EPS (Basic) (Quarter)	0.43	0.40	-0.12	0.15	0.44	-0.02	-0.22	-0.43	0.56	0.23	0.54	0.19	0.41	-3.11	0.35	0.10	-0.11	0.12	0.04	0.07
EPS (Weighted Average and Diluted) (Quarter)	0.42	0.39	-0.11	0.15	0.40	-0.02	-0.22	-0.43	0.51	0.23	0.52	0.19	0.39	-3.11	0.35	0.10	-0.11	0.12	0.04	0.07
Shares Outstanding (Weighted Average) (Quarter)	43.99M	44.15M	44.26M	44.87M	45.19M	45.83M	45.52M	45.95M	46.02M	46.15M	46.22M	46.50M	46.34M	46.27M	46.24M	46.27M	45.87M	44.04M	44.57M	40.46M
Shares Outstanding (Diluted Average) (Quarter)	45.59M	45.46M	45.63M	46.44M	52.48M	52.22M	46.54M	45.95M	46.28M	46.34M	51.98M	52.19M	50.54M	46.13M	46.24M	46.53M	45.46M	44.46M	45.04M	40.91M
EBITDA (Quarter)	34.84M	31.43M	4.21M	17.39M	31.23M	21.29M	-9.89M	-3.09M	39.88M	17.72M	33.17M	13.21M	28.24M	-139.53M	24.70M	1.99M	8.50M	6.36M	2.34M	6.90M
Interest Expenses (Quarter)	7.02M	7.33M	10.42M	10.25M	8.83M	9.86M	11.04M	9.59M	3.87M	3.46M	3.39M	3.32M	3.88M	4.69M	4.68M	4.58M	4.70M	4.28M	3.89M	3.70M
Tax Rate (Quarter)	25.60%	27.12%	17.23%	6.39%	9.68%	133.49%	44.09%	26.21%	31.94%	34.59%	26.25%	34.17%	48.38%	-3.32%	37.16%	44.73%	-151.53%	42.97%	-186.69%	41.66%

Research Tools

Pacira BioSciences Income Statement (2010-2026) | PCRX

Create an account

Sign In

Reset Password